Table 2 Relationship between FGF/FGFR dysregulation and immunotherapy
Tumor | Data sources | Mutation information | Results of immune monotherapy | Refs | |
|---|---|---|---|---|---|
FGFR dysregulation reduces immunotherapy efficacy | Locally advanced and unresectable or metastatic UC | NCT02365597 | FGFR Mutations /Fusions | 1 of 22 patients (5%) responded to previous immunotherapy | [9] |
Melanoma | GSE78220 | FGFR1/FGFR3 + | High FGFR1 + pts have Shorter OS; FGFR3 + pts have poorer PFS | ||
Advanced UC | Real world | FGFR+ | OS: FGFR+/FGFR- (3.1 mo vs. 6.1 mo, HR 1.33, 95% CI 0.78–2.26, p = 0.30) | [184] | |
Advanced UC | NCT03390504 | FGFR+ | FGFR + pts have shorter OS and lower ORR and DCR | [186] | |
NSCLC, Esophageal carcinoma etc. | Real world | FGF3/4/19 amplification | Tumor hyperprogression | [189] | |
FGFR dysregulation enhances immunotherapy efficacy | Melanoma | Real world | FGFR Mutations | FGFR + pts have better mOS and higher ORR | [193] |
Nonsmall cell lung cancer | Real world | FGFR4-altered | FGFR4-altered pts have better ORR and longer mPFS | [194] | |
FGFR dysregulation not associated with immunotherapy efficacy | Metastatic Advanced UC | IMvigor 210 + CheckMate 275 | FGFR3 Mutations | There was no statistically significant difference in response rate or OS | [20] |
Muscle-invasive Urothelial Bladder Carcinoma | NCT02736266. | FGFR3-altered | No correlation was found between FGFR3 activity or mutations/fusions and CR | [195] | |
UC | Real Worldv | FGFR3-altered | ORR:FGFR3-altered/FGFR-wild(12% vs. 19%, p = 0.73) | [66] |